Design and synthesis of new 1,2,4-oxadiazole/quinazoline-4-one hybrids with antiproliferative activity as multitargeted inhibitors
Introduction
The combination of BRAF and tyrosine kinase (TK) inhibitors has been demonstrated to be highly effective in inhibiting tumor development and is an approach for overcoming resistance in clinical trials. Accordingly, a novel series of 1,2,4-oxadiazole/quinazoline-4-one hybrids was developed as antiproliferative multitargeted inhibitors.
Methods
The structures of the newly synthesized compounds 9a-o were validated using IR, NMR, MS, and elemental techniques. 9a–o were tested as antiproliferative agents.
Results and Discussion
The results showed that the majority of the tested compounds showed significant antiproliferative action with 9b, 9c, 9h, 9k, and 9l being the most potent. Compounds 9b, 9c, 9h, 9k, and 9l were tested as EGFR and BRAFV600E inhibitors. These in vitro tests revealed that compounds 9b, 9c, and 9h are strong antiproliferative agents that may act as dual EGFR/BRAFV600E inhibitors. 9b, 9c, and 9h were further investigated for their inhibitory effect on mutant EGFR (EGFRT790M), and the results showed that the tested compounds had considerable inhibitory action. Cell cycle study and apoptosis detection demonstrated that compound 9b exhibits cell cycle arrest at the G2/M transition. Molecular docking simulations reveal the binding mechanism of the most active antiproliferative agents.
Top-30
Journals
|
1
2
3
|
|
|
Bioorganic Chemistry
3 publications, 18.75%
|
|
|
Journal of Molecular Structure
3 publications, 18.75%
|
|
|
RSC Advances
2 publications, 12.5%
|
|
|
Frontiers in Chemistry
2 publications, 12.5%
|
|
|
Pharmaceuticals
1 publication, 6.25%
|
|
|
Results in Chemistry
1 publication, 6.25%
|
|
|
European Journal of Medicinal Chemistry
1 publication, 6.25%
|
|
|
RSC Medicinal Chemistry
1 publication, 6.25%
|
|
|
Russian Chemical Reviews
1 publication, 6.25%
|
|
|
Journal of Sulfur Chemistry
1 publication, 6.25%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
7
8
|
|
|
Elsevier
8 publications, 50%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 18.75%
|
|
|
Frontiers Media S.A.
2 publications, 12.5%
|
|
|
MDPI
1 publication, 6.25%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 6.25%
|
|
|
Taylor & Francis
1 publication, 6.25%
|
|
|
1
2
3
4
5
6
7
8
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.